What is Zacks Research’s Estimate for Surmodics Q2 Earnings?

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of Surmodics in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of ($0.04) per share for the quarter, up from their prior forecast of ($0.05). The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.87 EPS.

Surmodics (NASDAQ:SRDX) last released its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Other research analysts also recently issued research reports about the stock. StockNews.com initiated coverage on shares of Surmodics in a research note on Monday, February 3rd. They issued a “hold” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Stock Performance

Shares of Surmodics stock opened at $35.54 on Monday. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The firm’s 50-day moving average is $36.83 and its 200 day moving average is $38.26. The stock has a market cap of $508.08 million, a price-to-earnings ratio of -35.19 and a beta of 1.20. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29.

Institutional Trading of Surmodics

A number of institutional investors have recently made changes to their positions in SRDX. Modus Advisors LLC bought a new position in Surmodics during the fourth quarter valued at approximately $40,000. Quest Partners LLC raised its stake in Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares during the last quarter. R Squared Ltd bought a new position in shares of Surmodics during the 4th quarter valued at $55,000. Longfellow Investment Management Co. LLC purchased a new position in shares of Surmodics in the 3rd quarter worth $67,000. Finally, Legal & General Group Plc boosted its stake in shares of Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after buying an additional 880 shares during the last quarter. Hedge funds and other institutional investors own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).